<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131375</url>
  </required_header>
  <id_info>
    <org_study_id>Dexmedetomidine.1.2017</org_study_id>
    <nct_id>NCT03131375</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia</brief_title>
  <official_title>Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia: a Prospective, Randomized, Double-blind, Single-center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athens General Children's Hospital &quot;Pan. &amp; Aglaia Kyriakou&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athens General Children's Hospital &quot;Pan. &amp; Aglaia Kyriakou&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine (DEX) is safe and effective in reducing ED following sevoflurane anesthesia.
      The investigators intend to study the efficacy of DEX in reducing ED in children undergoing
      tonsillectomy with and without adenoidectomy using total intravenous anesthesia (TIVA) with
      propofol .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emergence delirium in PACU</measure>
    <time_frame>up to 30 min</time_frame>
    <description>Presence or absence of Emergence delirium with and without dexmedetomidine assessed by Watcha scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergence delirium severity, assessed in PACU</measure>
    <time_frame>up to 30 min</time_frame>
    <description>Watcha score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extubation time</measure>
    <time_frame>up to15 min</time_frame>
    <description>time interval between discontinuation of anesthetics and extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>up to 45 min</time_frame>
    <description>monitored intraoperatively ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>up to 45 min</time_frame>
    <description>monitored intraoperatively NIBP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Emergence Delirium</condition>
  <condition>Extubation Time</condition>
  <condition>Heart Rate</condition>
  <condition>Postoperative Analgesia</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>alpha-2 agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bispectral index</intervention_name>
    <description>Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>BIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Train of four ratio</intervention_name>
    <description>Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>TOF-Watch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children

          -  ASA I or II

          -  tonsillectomy with or without adenoidectomy

        Exclusion Criteria:

          -  Allergy to dexmedetomidine

          -  Allergy to anesthetic drugs

          -  History of neurological disease

          -  History of neuromuscular disease

          -  History of renal disease

          -  History of hepatic disease

          -  craniofacial anomalies

          -  History of cardiac disease

          -  History of respiratory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangelia Kalliardou, Consultant</last_name>
    <role>Study Director</role>
    <affiliation>Director of the Anesthesiology Dept.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adelais G Tsiotou, Consultant</last_name>
    <phone>00306977516743</phone>
    <email>adeltsiotou@yahoo.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Malisiova, Consultant</last_name>
    <phone>00306936016546</phone>
    <email>malissanva@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens Hospital P. and A. Kyriakou Anesthesiology Department</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adelais Tsiotou, Consultant</last_name>
      <phone>00302132009435</phone>
      <email>adeltsiotou@yahoo.gr</email>
    </contact>
    <contact_backup>
      <last_name>Anna Malisiova, Consultant</last_name>
      <phone>00302132009434</phone>
      <email>malissanva@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Athens General Children's Hospital &quot;Pan. &amp; Aglaia Kyriakou&quot;</investigator_affiliation>
    <investigator_full_name>Adelais Tsiotou</investigator_full_name>
    <investigator_title>Consultant of the Anesthesiology Dept, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>emergence delirium</keyword>
  <keyword>anesthesia</keyword>
  <keyword>propofol</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

